title: Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants.
abstract: We compared the efficacy and safety of fluconazole and nystatin oral suspensions for the prevention of systemic fungal infection (SFI) in very low birthweight infants. A prospective, randomized clinical trial was conducted over a 15-month period, from May 1997 through September 1998, in 80 preterm infants with birthweights <1500 g. The infants were randomly assigned to receive oral fluconazole or nystatin, beginning within the first week of life. Prophylaxis was continued until full oral feedings were attained. Blood and urine cultures were obtained at enrollment and then weekly thereafter. Thirty-eight infants were randomly assigned to receive oral fluconazole (group I), and 42 infants were assigned to receive nystatin (group II). Birthweight, gestational age, and risk factors for fungal colonization and SFI at the time of randomization and during the hospital course were similar in both groups. SFI developed in two infants (5.3%) in group I and six infants (14.3%) in group II. The difference between these two rates was not statistically significant (relative risk, 0.37; 95% confidence interval, 0.08 to 1.72). There were no deaths in group I and six deaths in group II (P = 0.03). Two infants died of neonatal sepsis, and four deaths were related to necrotizing enterocolitis and/or spontaneous intestinal perforation. No deaths were due to SFI. Enrollment was halted before completion and the study did not attain adequate power to detect a hypothesized drop in SFI rate from 15 to 5%. Although the results cannot justify any conclusion about the relative efficacy of fluconazole versus nystatin in prevention of SFI, the significantly higher mortality rate in the nystatin group raises questions about the relative safety of this medication.
authors.affiliation: Division of Neonatology, Department of Pediatrics, Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia University, New York, New York 10032, USA. kv2145@columbia.edu
authors.forename: Kimon
authors.initials: K
authors.lastname: Violaris
authors.forename: Tracy
authors.initials: T
authors.lastname: Carbone
authors.forename: David
authors.initials: D
authors.lastname: Bateman
authors.forename: Olajide
authors.initials: O
authors.lastname: Olawepo
authors.forename: Brinda
authors.initials: B
authors.lastname: Doraiswamy
authors.forename: Meena
authors.initials: M
authors.lastname: LaCorte
mesh_terms: D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage*; D015725:Fluconazole / Q000008:administration & dosage*; D006801:Humans; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D009181:Mycoses / Q000188:drug therapy*; D009761:Nystatin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D009761:Nystatin; D015725:Fluconazole